Antikholinergicheskie preparaty dlya lecheniya bol'nykh s giperaktivnym mochevym puzyrem


Cite item

Full Text

Abstract

Гиперактивный мочевой пузырь (ГМП) – это клинический синдром, включающий ургентное мочеиспускание с наличием или без ургентного недержания мочи, обычно в сочетании с учащенным мочеиспусканием (число мочеиспусканий более 8 раз в сутки) и ноктурией (2 ночных пробуждения для мочеиспускания и более) [1]. Международное общество по удержанию (ICS) характеризует ГМП как синдром, не имеющий явной причины, а диагноз устанавливают на основании имеющихся симптомов нарушения мочеиспускания [1, 2]. Медикаментозными средствами первой линии для лечения больных с ГМП являются антихолинергические препараты. Они являются антагонистами мускариновых рецепторов, расположенных на гладких миоцитах детрузора, которые участвуют в регуляции тонуса детрузора парасимпатическими нервными волокнами. Несмотря на то что антихолинергические препараты уже в течение многих лет являются основными при лечении таких больных, их применение ограничено рядом аспектов, связанных с побочными эффектами.

About the authors

E. B Mazo

ГОУ ВПО РГМУ Росздрава, Москва

Кафедра урологии

M. E Shkol'nikov

ГОУ ВПО РГМУ Росздрава, Москва

Кафедра урологии

References

  1. Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the Standardization Sub - committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167–78.
  2. Van Kerrebroeck P, Abrams P, Chaikin D et al. The standardization of terminology in nocturia: report from the Standardization Sub - committee of the International Continence Society. Neurourol Urodyn 2002; 21: 179–83.
  3. Chapple C.R. Muscarinic receptor antagonists in yhe treatment of overactive bladder. Urology 2000; 55: 33–46; discussion 50.
  4. Andersson K.E., Appell R, Cardozo L.D. et al. The pharmacological treatment of urinary incontinence. BJU Int 1999; 84: 923–47.
  5. Andersson K.E., Yoshida M. Antimuscarinics and the overactive detrusor – which is the main mechanism of action? Eur Urol 2003; 43: 1–5.
  6. Pak R.W., Petrou S.P., Staskin D.R. Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr Urol Rep 2003; 4: 436–40.
  7. Schwantes U, Topfmeier P. Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia– chances for improvement of therapy. Int J Clin Pharmacol Ther 1999; 37: 209–18.
  8. Pontari M.A., Braverman A.S., Ruggieri M.R. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol 2004; 286: R874–80.
  9. Fetscher C, Fleichman M, Schmidt M et al. M3 muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 2002; 136: 641–3.
  10. Yoshimura N, Chancellor M.B.: Current and future pharmacologic treatment for overactive bladder. J Urol 2002; 168: 1897–913.
  11. Fisher A, Michaelson D.M., Brandeis R et al. M1 muscarinic agonists as potential disease - modifying agents in Alzheimer’s disease. Rationale and perspectives. Ann N Y Acad Sci 2000; 920: 315–20.
  12. Thuroff J.W., Chartier-Kastler E, Corcus J et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 1998; 16 (Suppl. 1): 548–61.
  13. Diokno A.C., Appell R.A., Sand P.K. et al. Prospective, randomized, double - blind study of the efficacy and tolerability of the extended - release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78: 687–95.
  14. Daliva G.W., Daugherty C.A., Sanders S.W., transdermal Oxybutinin Study Group. A short - term, multicenter, randomized double - blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutinin treatment of patients with urge urinary incontinence. J Urol 2001; 166: 140–5.
  15. Appell R.A. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50: 90–6.
  16. Van Kerrebroeck P, Kreder K, Jonas U et al. Tolterodine Study Group. Tolterodine once - daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001; 57: 414–21.
  17. Kim Y, Yoshimura N, Masuda H et al. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Int 2005; 97: 400–3.
  18. Lips K.S., Wunsch J, Zarghooni S et al. Acetylcholine and molecular components of its synthesis and release machinery in the urothelium. Eur Urol 2007; 51 (4): 1042–53.
  19. Singh-Franco D, Machado C, Tuteja S, Zapantis A. Trospium Chloride for the Treatment of Overactive Bladder with Urge Incontinence. Clin Therap 2005; 27 (5): 511–30.
  20. Zinner N, Gittelman M, Harris R et al; Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171 (6 Pt 1): 2311–5.
  21. Sanctura (trospium chloride) tablets [package insert]. East Hanover, NJ: Odyssey Pharmaceuticals, 2004.
  22. Hashim H, Abrams P. Drug treatment of overactive bladder: eicacy, cost and quality - of - life considerations. Drugs 2004; 64 (15): 1643–56.
  23. Jnemann K.P., Al-Shukri S. Eicacy and tolerability of trospium chloride and tolterodine in 234 patients with urge - syndrome: a double - blind, placebo - controlled, multicentre clinical trial [abstract 85B]. Neurourol Urodyn 2000; 19 (4): 488–90.
  24. Madersbacher H, Stohrer M, Richter R et al. Trospium chloride versus oxybutynin: a randomized, double - blind, multicentre trial in the treatment of detrusor hyperreflexia. Br J Urol 1995; 75 (4): 452–6.
  25. Staskin D, Sand P, Zinner N, Dmochowsk R, Trospium Study Group. Once Daily Trospium Chloride is Effective and Well Tolerated for the Treatment of Overactive Bladder: Results From a Multicenter Phase III Trial. J Urol 2007; 178: 978–84.
  26. Мазо Е.Б., Бабанина Г.А. Троспий хлорид (спазмекс) в лечении симптомов нижних мочевых путей у больных с нейрогенным гиперактивным мочевым пузырем вследствие вертеброгенных поражений. Урология. 2007; 3: 15.
  27. Доброхотова Ю.Э., Мазо Е.Б., Кривобородов Г.Г. и др. Троспия хлорид в лечении женщин с симптомами гиперактивного мочевого пузыря, сохранившимися после хирургической коррекции пролапса гениталий. Вестн. РГМУ. 2007; 3 (56).
  28. Chapple C, Wyndaele J.J., Gronen S, for the Solifenacin Study Group. Solifenacin provided statistically significant and clinically relevant reductions in urgency, a defining symptom of overactive bladder. Neurourol Urodyn 2004; 23: 316.
  29. Chapple C.R., Arano P, Bosch J.L. et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placeboand tolterodine - controlled phase 2 dose - finding study BJU Int 2004; 93: 71–7.

Copyright (c) 2008 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies